RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Lei WangSebastian S DeMarcoMary Stuart PeaksAbigail L Maiorana-BoutilierJianMing ChenMiranda J CrouchBrian M ShewchukSaame Raza ShaikhCharles M PhillipsLance C BridgesPublished in: Experimental dermatology (2017)
Retinoids, natural and synthetic derivatives of vitamin A, induce cellular changes by activating nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR). Although the ability of retinoids to govern gene expression is exploited clinically for cancer therapeutics, the full benefit of retinoid-based strategies is unrealized due to detrimental side effects. Delineating the receptors that prompt cellular outcomes is critical to advancing retinoid-based approaches. Here, we identify the receptors that evoke multiple responses in cutaneous T-cell lymphoma (CTCL). The data demonstrate that RARα drives integrin β7-dependent adhesion and CCR9-mediated chemotaxis in CTCL cells. Of note, concomitant activation of RARα and RXR nuclear receptors yielded synergistic increases in adhesion and migration at concentrations where single agents were ineffective. As the established paradigm of retinoid action in CTCL is apoptosis and growth arrest, the role of RARα/RXR in these events was studied. As with adhesion and migration, RARα/RXR synergism prompted apoptosis and dampened CTCL cell proliferation. Strikingly, RARα/RXR synergism induced responses from CTCL cell lines previously reported to be unresponsive to retinoids. These data provide a novel framework that may further refine a proven CTCL therapy.
Keyphrases
- cell cycle arrest
- gene expression
- cell proliferation
- oxidative stress
- cell death
- electronic health record
- induced apoptosis
- big data
- dna methylation
- type diabetes
- squamous cell carcinoma
- papillary thyroid
- small molecule
- high glucose
- dendritic cells
- stem cells
- drug induced
- staphylococcus aureus
- deep learning
- replacement therapy
- weight loss
- smoking cessation